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Objectives: 
1. Explain the screening, diagnosis, and pathophysiology of diabetic nephropathy 
2. Describe the renin-angiotensin-aldosterone system (RAAS) and the mechanism of action and effects of 
angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (ARB) 
3. Review the current guidelines and treatment recommendations for diabetic nephropathy 
4. Evaluate the available literature regarding the effects of RAAS on diabetic nephropathy in normoalbuminuric 
patients Diabetic nephropathy: Do all patients with Diabetes Mellitus benefit from an ACE-I or ARB?  2 
I.  Introduction  
a.  Diabetes Mellitus (DM)1 
i.  Type 1 (T1DM) 
1.  Insulin-dependent DM (IDDM) 
2.  Autoimmune destruction of β cells in pancreas 
3.  Accounts for 5-10% of all diagnosed cases of DM 
ii.  Type 2 (T2DM) 
1.  Non-insulin dependent DM (NIDDM) 
2.  Insulin resistance and relative deficiency in insulin secretion 
3.  Accounts for 90-95% of all diagnosed cases of DM 
b.  Prevalence of diagnosed and undiagnosed diabetes in the United States, all ages, 20071 
i.  Affects nearly 24 million people in the United States  8% of population 
ii.  Diagnosed: 17.9 million people 
iii.  Undiagnosed: 5.7 million people 
c.  Prevalence of diagnosed and undiagnosed diabetes in the United States, > 20 years old, 20071  
i.  Age > 20 years: 23.5 million people 
ii.  Age > 60 years: 12.2 million people 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Estimated prevalence of diagnosed and undiagnosed diabetes in > 20 year olds1 
 
 
d.  Incidence of diagnosed diabetes among people aged > 20 years old, 20071 
i.  About 1.6 million new cases 
e.  Estimated costs of DM in 20071 
i.  Total (direct and indirect): $174 billion 
ii.  Managing diabetic nephropathy2 
1.  T1DM: $1.9 billion 
2.  T2DM: $15 billion 
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f.  Complications of DM1 
i.  Microvascular  
1.  Nephropathy 
2.  Retinopathy 
a.  Leading cause of new cases of blindness among adults aged 20-74 years 
b.  Causes 12,000 to 24,000 new cases of blindness each year 
3.  Neuropathy 
a.  About 60-70% of people have mild to severe forms of nervous system damage 
i.  Impaired sensation in hands or feet, slowed digestion of food in stomach, carpal 
tunnel syndrome, erectile dysfunction  
ii.  Macrovascular 
1.  Heart disease 
a.  Death rates about 2 to 4 times higher than adults without DM 
2.  Stroke 
a.  Risk of stroke is 2 to 4 times higher among people with DM 
g.  Preventing complications1 
i.  Glycemic control 
1.  Every percentage point drop in HgbA1c, can reduce risk of microvascular complications by 
40% 
ii.  Blood pressure (BP) control 
1.  Reduces risk of cardiovascular disease (heart disease or stroke) by 33-50% 
2.  Reduces risk of microvascular complications by 33% 
3.  For every 10 mmHg reduction in systolic blood pressure (SBP), risk of any complication 
related to DM is reduced by 12% 
iii.  Lipid control 
1.  Improved control of LDL can reduce cardiovascular complications by 20-50% 
 
II.  Diabetic nephropathy 
a.  Background3 
i.  Occurs in 20-40% of patients with DM 
ii.  Single leading cause of end stage renal disease (ESRD)1 
1.  44% of new cases of kidney failure in 2005 
iii.  Associated with increased cardiovascular mortality 
iv.  Earliest clinical abnormality = microalbuminuria4 
1.  Occurs between 5-15 years after onset of T1DM or T2DM 
v.  Symptomatic kidney failure = worsening albuminuria, increases in BP, and decreasing glomerular 
filtration rate (GFR) 4 
1.  Around 20 years after onset of T1DM or T2DM 
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b.  Definition3 
i.  Increased urinary albumin excretion (UAE) in the absence of other renal diseases 
ii.  Presumptive diagnosis of kidney disease caused by diabetes 
iii.  Categorized into stages3,5 
1.  Microalbuminuria 
a.  Modest elevation of albumin 
b.  Associated with stable kidney function 
c.  Greater risk of macroalbuminuria and kidney failure 
2.  Macroalbuminuria 
a.  Higher elevation of albumin 
b.  Associated with progressive decline in GFR and increase in systemic blood pressure, and 
high risk of kidney failure 
c.  Risk factors3 
i.  Hyperglycemia 
ii.  Elevated blood pressure 
iii.  Genetic predisposition 
iv.  Hyperlipidemia 
v.  Smoking 
vi.  Dietary protein intake 
d.  Pathophysiology6,7 
i.  Hemodynamic changes 
1.  Hyperfiltration and hyperperfusion 
a.  Found early in disease process 
b.  Elevation in glomerular capillary pressure causes an enhanced transcapillary hydraulic 
pressure gradient and increase in glomerular plasma blood flow 
i.  Decrease in both afferent and efferent arteriole resistance 
1.  Afferent more dilated than efferent  increased glomerular capillary pressure 
2.  Defect in autoregulation 
c.  Prostanoids, nitrogen oxide (NO), atrial natriuretic factor, growth hormone, glucagon, 
insulin, angiotensin II (ANG II) 
d.  Elevated intraglomerular pressure linked to an increase in mesangial cell matrix 
production and thickening of glomerular basement membrane  glomerulosclerosis 
e.  Vascular endothelial growth factors (VEGFs) induced by diabetic environment 
f.  Cytokines, such as transforming growth factor beta (TGF-β) 
i.  Dilatation of vas afferens by inhibiting calcium transients 
ii.  Increases NO production 
ii.  Inflammation 
1.  Up-regulation of genes of inflammatory and vasoactive mediators in proximal tubular cells 
2.  Result in renal scarring 
iii.  Pathological changes 
1.  Hyperglycemia induces mesangial hypertrophy and thickening of glomerular basement 
membrane 
2.  Increased in amount of matrix in mesangium  progresses to sclerosis of glomerular 
capillaries 
a.  Sclerotic changes (usually after ~ 10 years of diabetes) classified by 
i.  Diffuse, nodular, or both Diabetic nephropathy: Do all patients with Diabetes Mellitus benefit from an ACE-I or ARB?  5 
3.  As glomerulus becomes more fibrotic and scarred  loses function and ESRD results 
4.  May also see afferent and efferent glomerular arteriolar thickening, tubular basement 
membrane thickening, and increased volume of interstitium 
 
e.  Screening and diagnosis5,8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Screening and diagnosis of diabetic kidney disease5 
 
i.  Assess UAE yearly in  
1.  T1DM patients with diabetes > 5 years 
2.  T2DM patients at diagnosis 
ii.  Measure serum creatinine yearly in 
1.  All adults with DM regardless of degree of UAE 
2.  Used to estimate GFR and stage of chronic kidney disease (CKD), if present 
iii.  Measure albumin-to-creatinine ratio in random spot collection (preferred method) 
1.  Two of three specimens collected within a 3 to 6 month period should be abnormal before a 
diagnosis or micro- or macroalbuminuria can be made 
a.  Some conditions may cause a transient increase in UAE 
i.  Exercise within 24 hours, infection, fever, CHF, marked hyperglycemia, hypertension 
iv.  Can attribute CKD to DM in patients with the following 
1.  Presence of macroalbuminuria 
2.  Presence of microalbuminuria 
a.  In presence of diabetic retinopathy 
b.  In T1DM of > 10 years duration 
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Table 1.  Definitions of abnormalities in albumin excretion5 
Category  Spot collection 
(mg/g creatinine) 
24 hour collection 
(mg/24 hr) 
Timed collection 
(mcg/min) 
Normoalbuminuria  < 30  < 30  < 20 
Microalbuminuria  30-300  30-300  20-200 
Macroalbuminuria  > 300  > 300  > 200 
 
 
III.  Treatment in Diabetic Nephropathy 
a.  General recommendations to reduce risk or slow progression of nephropathy5,8 
i.  Optimize glucose control (HgbA1c < 7%) 
ii.  Optimize blood pressure (BP) control (< 130/80 mmHg) 
b.  Intensive management of glycemic control has been shown to delay the onset of microalbuminuria and 
progression of microalbuminuria to macroalbuminuria 
i.  Preventing development of microalbuminuria 
 
Table 2.  Summary of trials: preventing development of microalbuminuria 
Trial  Population  N  Renal endpoint  Treatment  Duration  Results 
DCCT9 
T1DM without (1o 
prevention) and 
with (2o 
intervention) 
retinopathy at 
baseline; 
normotensive; 
normoalbuminuria 
or 
microalbuminuria 
1441  Occurrence of 
microalbuminuria 
IT (A1c 7.2%) vs 
CT (A1c 9.1%)  6.5 years 
Intensive 
therapy: 
reduced by 
34% (1o 
prevention) 
and 43 % (2o 
intervention) 
EDIC10 
T1DM 
Normoalbuminuria 
at beginning and 
end of DCCT 
1349 
Occurrence of 
new cases of 
microalbuminuria 
IT (A1c 8%) vs 
CT (A1c 8.2%) 
8 year post 
final DCCT 
visit 
6.8% vs 
15.8% 
Kumamoto11 
T2DM without 
hypertension (1o 
prevention cohort 
vs 2o intervention) 
110 
New onset and 
progressive 
diabetic kidney 
disease 
IT (A1c 7.1%) vs 
CT (A1c 9.4%)  6 years  7.7% vs 28% 
UKPDS 3312  Newly diagnosed 
T2DM  3867  Development of 
microalbuminuria 
IT (insulin or 
sulfonylurea) 
(A1c 7%) vs CT 
(diet) (A1c 7.9%) 
9 years  24% relative 
risk reduction 
VA 
Cooperative 
Study13 
T2DM with no 
microalbuminuria  95  Development of 
microalbuminuria 
IT (A1c 7.1%) vs 
CT (A1c 9.2%)  2 years  17% vs 35% 
IT: intensive therapy; CT: conventional therapy 
DCCT: 10 prevention – no retinopathy and UAE < 28 mcg/min at baseline; 20 intervention – background retinopathy with or without 
microalbumoinuria, but normal GFR 
Kumamoto: 10 prevention – no retinopathy and UAE < 30 mg/24 hr; 20 intervention – simple retinopathy and UAE < 300 mg/24 hr 
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ii.  Preventing development of macroalbuminuria 
 
Table 3.  Summary of trials: preventing development of macroalbuminuria 
Trial  Population  N  Renal endpoint  Treatment  Duration  Results 
DCCT9 
T1DM without (1o 
prevention) and 
with (2o 
intervention) 
retinopathy at 
baseline 
1441  Occurrence of 
macroalbuminuria 
IT (A1c 7.2%) vs 
CT (A1c 9.1%)  6.5 years  0.8% vs 
5.6% 
EDIC10  T1DM  1349  New cases of 
macroalbuminuria 
IT vs CT (A1c ~ 
8% in both 
groups at this 
time) 
8 year post 
final DCCT 
visit 
1.4% vs 
9.4% 
Stockholm14 
T1DM with 
nonproliferative 
retinopathy 
102  Development of 
macroalbuminuria 
IT (A1c 7.1%) vs 
CT (A1c 8.5%)  7.5 years  2.1% vs 
16.6% 
Kumamoto11 
T2DM without 
hypertension (1o 
prevention cohort 
vs 2o intervention) 
110  Progression to 
macroalbuminuria 
IT (A1c 7.1%) vs 
CT (A1c 9.4%)  6 years  11.5% vs 
32% 
UKPDS 3312  Newly diagnosed 
T2DM  3867  Development of 
macroalbuminuria 
IT (insulin or 
sulfonylurea) 
(A1c 7%) vs CT 
(diet) (A1c 7.9%) 
9 years 
33% relative 
risk 
reduction+ 
VA 
Cooperative 
Study13 
T2DM with 
microalbuminuria  95  Development of 
macroalbuminuria 
IT (A1c 7.1%) vs 
CT (A1c 9.2%)  2 years  12% vs 36% 
ADVANCE15 
T2DM with h/o 
macro- or 
microvascular 
disease or one 
other risk factor 
for vascular 
disease 
11140  Development of 
macroalbuminuria 
IT (A1c 6.5%) vs 
CT (A1c 7.3%)  5 years  2.9% vs 
4.1% 
IT: intensive therapy; CT: conventional therapy 
+ Not statistically significant 
 
 
c.  Protein restriction8 
i.  May improve measures of renal function 
ii.  In patients with DM and earlier stages of CKD 
1.  Reduction of protein intake to 0.8-1 g/kg/day 
iii.  In patients with later stages of CKD 
1.  Reduction of protein intake to 0.8 g/kg/day 
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d.  Pharmacotherapy 
i.  RAAS blockade8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 3.  Effects of renin-angiotensin-aldosterone system16 
 
ii.  Inhibition of RAAS effective in preventing diabetic nephropathy17 
iii.  Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) 
1.  Mechanism of action of ACE-I18 
a.  Prevents the conversion of angiotensin I to angiotensin II 
b.  Decreased angiotensin II levels 
i.  Decreased vasopressor activity and decreased aldosterone secretion 
2.  Mechanism of action of ARB19 
a.  Reversible angiotensin II receptor antagonist 
b.  Deters vasoconstriction and aldosterone secreting effects by binding to the angiotensin II 
(AT1) receptor 
3.  ACE-I and ARB side effects18,19 
a.  Hyperkalemia, acute kidney injury, cough (seen more with ACE-I), angioedema 
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iv.  Effects on diabetic nephropathy8,20 
 
 
 
       
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  ACE-I vs ARB in progressive nephropathy associated with T2DM21 
 
1.  ACE-Is have been shown to reduce major cardiovascular disease (CVD) outcomes in patients 
with DM  supports using in patients with microalbuminuria, a risk factor for CVD 
2.  ARBs have been shown to reduce rate of progression from microalbuminuria to 
marcoalbuminuria as well as ESRD 
3.  Attributed to decrease in BP, dilatation of efferent arterioles, improved endothelial function, 
reduced inflammation, and vasoprotective effects  
 
v.  KDOQI guidelines recommends5 
1.  ACE-Is and ARBs effective in slowing progression of kidney disease (microalbuminuria) in 
T1DM or T2DM patients with hypertension 
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vi.  Trials supporting use of ACE-I or ARB in diabetic nephropathy 
 
Table 4.  Summary of landmark trials: ACE-I or ARB for diabetic nephropathy 
Trial  Population  N  Endpoint  Treatment  Duration  Results 
Collaborative 
Study Group22 
T1DM with 
retinopathy and UAE 
> 500 mg/24 hr* 
409  UAE and doubling 
of SCr 
Captopril 25 
mg TID vs 
placebo 
3 years 
UAE: decrease of 
0.3g/24 hr with 
captopril 
(p=0.001) 
Doubling of SCr: 25 vs 
43 (p=0.007) 
MICRO-
HOPE23 
T2DM with h/o CVD 
or CV risk factor 
without or with 
microalbuminuria 
3577  Overt nephropathy 
Ramipril 10 mg 
daily vs 
placebo 
4.5 years 
Relative risk of overt 
nephropathy reduced 
by 24%; without 
baseline 
microalbuminuria, 
relative risk of 
developing 
microalbuminuria 
reduced by 9%+ 
ONTARGET24 
T2DM with 
atherosclerotic 
vascular disease or 
endorgan damage; 
without micro- or 
macroalbuminuria 
25,620 
Progression of 
proteinuria --> new 
development of 
micro- or 
macroalbuminuria 
Ramipril 10 mg 
daily or 
telmisartan 80 
mg daily or 
combination of 
both 
56 
months 
11.7% (R) vs 11.1% 
(T)+  
11.7% (R) vs 10.4% 
(C) ++ 
IDNT25 
T2DM with HTN or 
HTN treatment with 
UAE > 900 mg/24 hr 
1715  Reduction in 
proteinuria 
Irbesartan 300 
mg daily vs 
amlodipine 10 
mg daily vs 
placebo 
2.6 years  33% vs 6% vs 10% 
Parving et al26  T2DM with HTN with 
microalbuminuria  590 
Reduction in level 
of UAE; 
occurrence of 
restoration of 
normoalbuminuria 
Irbesartan 150 
mg daily vs 
irbesartan 300 
mg daily vs 
placebo  
2 years  24% vs 38% vs 2%; 
24% vs 34% vs 21% 
RENAAL27  T2DM with HTN with 
macroalbuminuria  1513 
Reduction in level 
of proteinuria 
(urinary 
albumin:creatinine) 
Losartan 100 
mg daily vs 
placebo  
3.4 years  35% with losartan vs 
increase with placebo 
* About 75% of patients in each group were hypertensive 
+ Not statistically significant; ++ Statistically significant 
 
1.  Majority of these trials included patients who were hypertensive or had CVD risks and already 
had micro- or marcoalbuminuria 
a.  In patients with HTN and/or micro- or macroalbuminuria, ACE-I or ARB are beneficial in 
reducing proteinuria 
 
IV.  Literature reviewing effectiveness of ACE-I or ARB in patients without albuminuria or with 
microalbuminuria 
a.  Hypertensive patients or patients with cardiovascular disease without albuminuria28 
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Ruggenenti P, Fassi A, Ilieva AP, et al.  Preventing microalbuminuria in Type 2 Diabetes (BENEDICT).  N Engl J Med 
2004;351:1941-1951. 
Design    Double-blind, placebo-controlled, randomized, multicenter 
Objective    Examine the effects of an ACE-I + a non-dihydropyridine calcium channel blocker (CCB), ACE-I alone, CCB 
alone, or placebo in preventing microalbuminuria when given to patients with hypertension, T2DM, and 
normal UAE 
Population    n = 1204; followed for a median of 3.6 years 
  Inclusion criteria: > 40 years old, hypertension (untreated with BP > 130/85 mmHg or treated with BP < 
130/85 mmHg), known history of T2DM < 25 years, UAE < 20 mcg/min, (2 of 3 consecutive, sterile, overnight 
samples), SCr < 1.5 mg/dL 
  Exclusion criteria: HgbA1c > 11%, nondiabetic renal disease, specific indication for or contraindication to 
ACE-I or non-dihydropyridine CCB 
Endpoints    Primary 
  Development of persistent microalbuminuria 
  Secondary 
  Follow up systolic and diastolic blood pressure 
Protocol    6 week washout period where any previous ACE-I was discontinued and 3 week washout period where any 
previous CCB was discontinued 
  Groups 
  Trandolapril 2 mg daily + verapamil 180 mg daily (sustained release) 
  Trandolapril 2 mg daily 
  Verapamil 240 mg daily (sustained release) 
  Placebo 
  Target BP 120/80 mmHg 
  Additional antihypertensives were allowed to achieve target BP 
  Use of potassium-sparring diuretics, RAAS inhibitors, non-dihydropyridine CCB not allowed 
  Target HgbA1c < 7% 
  Magnitude of treatment effect assessed by calculating acceleration factor  quantifies the effect of one 
treatment relative to another treatment in accelerating or slowing the progression of the disease 
Results    Baseline characteristics similar between groups 
  Statistically significant difference in BP in patients receiving ACE-I; no major differences in blood glucose 
levels and lipid profiles among treatment groups 
Outcomes  ACE-I + CCB 
(n=300) 
ACE-I alone 
(n=301) 
CCB alone 
(n=303) 
Placebo 
(n=300) 
Development of 
persistent 
microalbuminuria 
17 (5.7%)  18 (6%)  36 (11.9%)  30 (10%) 
Estimated 
acceleration factor 
(95% CI) 
0.39 
(0.19 to 0.8) 
0.47 
(0.26 to 0.83) 
0.83 
(0.45 to 1.51)   
p-value  0.01  0.01  0.54   
Delaying onset of 
microalbuminuria 
factor 
2.6  2.1  NS   
 
Outcomes  ACE-I vs no ACE-I onboard  CCB vs no CCB on board 
Development of persistent 
microalbuminuria  35/601 (5.8%) vs 66/603 (10.9%)  53/603 (8.8%) vs 48/601 (8%) 
Delaying onset of 
microalbuminuria factor  2.3  NS 
 
Authors’ 
Conclusions 
  Treatment with combo ACE-I + CCB or ACE-I alone significantly reduces incidence of microalbuminuria in 
patients with T2DM and normal UAE compared to placebo 
Comments    Patients with hypertension (ACE-I or ARB known to be beneficial for BP lowering) 
  Average trough BP significantly lower in the groups receiving trandolapril alone or in combination versus 
placebo group  Diabetic nephropathy: Do all patients with Diabetes Mellitus benefit from an ACE-I or ARB?  12 
b.  Normotensive without albuminuria or with microalbuminuria29,30,31 
 
The EUCLID study group.  Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent 
diabetes and normoalbuminuria or microalbuminuria.  Lancet 1997;349:1787-1792. 
Design    Double-blind, placebo-controlled, randomized, multicenter 
Objective    Assess whether early-stage intervention in patients without hypertension would limit progression of renal 
disease, and whether this effect differed according to degree of albuminuria 
Population    n = 530; followed for 2 years 
  Inclusion criteria: men and women between 20-59 yr old with insulin-dependent diabetes (IDDM), BP < 
155/75-90 mmHg 
  Exclusion criteria: h/o renal artery stenosis, cardiac-valve obstruction, or accelerated hypertension, recent 
myocardial infarction, CABG, stroke, congestive cardiac failure, abnormal renal function (SCr > 1.8 mg/dL) in 
previous 6 months, persistent proteinuira (albumin excretion rate (AER) > 250 mcg/min), persistent 
haematuria, postural hypotension, medications that affects BP, seropositivity for Hepatitis B or HIV 
Endpoints    Primary 
  Rate of change in AER 
Protocol    One month run in with placebo tablets and made two consecutive timed overnight urine collections just before 
randomization visit 
  Randomization stratified by albuminuric status 
  Normoalbuminuric group  average of two results indicated that albumin concentration < 15 mg/L 
  Microalbuminuric group  higher average concentrations 
  Groups 
  Lisinopril (n = 265) 
  Placebo (n = 265) 
  AER and HgbA1c assessed every 6 months 
  Starting dose of lisinopril was 10 mg daily  could be increased to 20 mg at 3 months and subsequent visits 
to achieve a target diastolic BP < 75 mmHg 
Results    Baseline characteristics similar between groups 
  Both groups had similar HgbA1c levels during the trial 
  Mean diastolic BP = 74 mmHg on active treatment and 77 mmHg on placebo (p=0.0001) – difference carried 
throughout trial 
  In the intention-to-treat group, after 2 years (lisinopril n = 244; placebo n = 246) 
  AER was 2.2 mcg/min lower in the treatment than in the placebo group 
  Relative treatment difference in AER at 2 years was 24% (p=0.02) 
  Adjustment made for baseline AER and centre, difference persisted  at 2 years, AER was 18.8% lower 
in the treatment than in the placebo group (2, 32.7; p=0.03) 
  Adjustment for diastolic BP at 1 month  reduced percentage difference in AER at 2 years to 17.3% (0.2, 
31.5; p=0.05) 
  Normoalbuminuric at baseline  AER at 2 years was 12.7% (-2.9 to 26; p=0.1) lower in the treatment 
than in the placebo group; absolute difference of 1 mcg/min 
  Microalbuminurc at baseline  AER at 2 years was 49.7% (-14.5 to 77.9; p=0.1) lower in the treatment 
than in the placebo group; absolute difference of 34.2 mcg/min 
  Separate analysis done to compare actual mean AER at 2 yr visit (only included patients who attended final 
visit) (lisinopril n = 233; placebo n = 232) 
  Normoalbuminuric at baseline  treatment difference in mean AER was 0.23 mcg/min (p=0.6) 
  Microalbuminuric at baseline  treatment difference in mean AER was 38.5 mcg/min (p=0.001) 
Authors’ 
Conclusion 
  Lisinopril slows progression of AER in a mixed population of normoalbuminuric and microalbuminuric 
normotensive T1DM patients 
  Greatest effect seen in patients with baseline microalbuminuria (AER > 20 mcg/min) 
Comments    Short term study; however, most likely long enough because average duration of diabetes was 13 years  
  Different results (statistically significant or not) depending on whether ITT is used or including patients who 
attended final visit 
  Variations in duration of diabetes and glycemic control  could be applied to a wide variety of patients 
(duration of diabetes ranged from 9-20 years and HgbA1c ranged from 5.6%-8.4%) Diabetic nephropathy: Do all patients with Diabetes Mellitus benefit from an ACE-I or ARB?  13 
Bilous R, Chaturvedi N, Sjølie A, et al.  Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes 
(DIRECT-Renal).  Ann Intern Med 2009;151:11-20. 
Design    Three double-blind, placebo-controlled, randomized, multicenter 
Objective    Investigate whether the ARB, candesartan, compared with placebo affects microalbuminuria incidence or rate 
of change in albuminuria in T1DM and T2DM 
Population    n = 5231 (pooled sample); followed for a median of 4.7 years 
  Inclusion criteria:  
  DIRECT-Prevent 1: Patients with T1DM and no retinopathy, normoalbuminuria, normotensive 
  DIRECT-Protect 1: Patients with T1DM with evidence of retinopathy, normoalbuminuia, normotensive 
  DIRECT-Protect 2: Patients with T2DM with evidence of retinopathy, normoalbuminuria, normotensive or 
treated with an antihypertensive (other than a RAAS inhibitor) 
Endpoints    Primary (a priori-determined) 
  Development of microalbuminuria 
  Secondary (a priori-determined) 
  Rate of change in UAE rate 
Protocol    One month run in with placebo tablets and made two consecutive timed overnight urine collections just before 
randomization visit 
  Randomization stratified by hypertensive status in the DIRECT-Protect 2 only 
  Groups 
  Candesartan 16 mg daily increasing to 32 mg daily after 1 month (n = 2613) 
  Placebo (n = 2618) 
  UAE rate assessed at baseline and annually thereafter 
  Lower limit of detection of albumin concentration was 20 mcg/L 
  In patients who developed microalbuminuira (UAE rate > 20 mcg/min) in 1 or both urine samples at any time 
to provide 2 more samples  if 3 or 4 of these 4 consecutive samples were positive = microalbuminuria 
  Patients who were or became hypertensive (BP > 140/85 mmHg) but UAE rate remained normal could be 
initiated on any non-RAAS blocking antihypertensive agent 
Results    BP was lower in candesartan group than in placebo group by end of study (p<0.001) 
  Number of patients who developed microalbuminuria did not differ between groups, regardless of previous 
antihypertensive therapy 
Incidence of microalbuminuria  Candesartan  Placebo 
T1DM (2 studies)  5%  5% 
T2DM  12%  13% 
  For the pooled study population, the unadjusted HR (candesartan vs placebo) was 0.95 (95% CI, 0.78 to 1.16; 
p =0.60) 
  A significant reduction of 5.53%  in UAE rate occurred in pooled study population; absolute reduction of 0.11 
mcg/min 
Authors’ 
Conclusion 
  Candesartan had no effect on incidence of microalbuminuria over 4.7 years in normoalbuminuric and 
normotensive patients with T1DM and normoalbuminuric patients with T2DM with or without treated HTN 
  Adjusted rate of change in UAE rate was statistically significant; however, clinical significance uncertain 
  Do not recommend use of candesartan or other RAAS blocking agents in primary prevention of diabetic 
nephropathy in patients with T1DM or T2DM and a low vascular burden 
Comments    Limited generalizability (>50% male and >95% Caucasian) 
  High proportion of patients in placebo group received open-label RAAS inhibitors – did not change 
microalbuminuria outcomes 
  High percent who withdrew consent (9.6%) – patients who withdrew more likely to have had progressive 
disease and higher event rates  lower event rate in remaining patients 
  Different results in T2DM patients (compared to HOPE, BENEDICT, ADVANCE)  T2DM patients in 
DIRECT-Renal had a low burden of vascular damage; therefore, decreased vascular RAAS activity 
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Mauer M, Zinman B, Gardiner R, et al.  Renal and retinal effects of enalapril and losartan in type 1 diabetes (RASS).  N Engl J 
Med 2009;361:40-51. 
Design    Double-blind, placebo-controlled, randomized, multicenter 
Objective    Assess the effect of renin-angiotensin blockade with either an ACE-I or ARB on both renal and retinal 
morphological features in normotensive patients with T1DM and normoalbuminura 
Population    n = 285; followed for 5 years 
  Exclusion criteria: hypertension (BP > 135/85 mmHg or receiving an antihypertensive), albumin excretion rate 
(AER) > 20 mcg/minute, pregnancy, failure to be adherent with placebo tablets during 2 week run-in period, 
GFR < 90 mL/min 
Endpoints    Primary 
  Change in fraction of glomerular volume occupied by mesangium (the mesangial fractional volume) 
  Secondary 
  Changes in other glomerular, vascular, tubular, and interstitial variables and changes in the albumin 
excretion rate and GFR 
Protocol    Groups 
  Enalapril 10 mg daily 
  Losartan 50 mg daily 
  Placebo 
  During study, doses were doubled (received doubled doses for 2.9+0.9 years) 
  BP, albumin excretion rate, and HgbA1c obtained quarterly; GFR assessed yearly 
  Target BP < 130/80 mmHg 
  Additional antihypertensives were allowed to achieve target BP if hypertension persisted for 2 weeks 
  Use a medication that does not block renin-angiotensin system 
  Microalbuminuria = mean of at least two of three consecutive values between 20 and 200 mcg/min 
  Percutaneous biopsy preformed before randomization and 5 years later 
Results    Baseline characteristics similar between groups 
  Three groups had similar HgbA1c levels (p=0.54) and insulin doses (p=0.29) during the 5 year period 
  Will not report retinopathy results – see article for full results 
 
Outcomes  Enalapril 
(n=94) 
Losartan 
(n=96) 
Placebo 
(n=95) 
Mesangial fractional volume 
   Mean at baseline 
   Mean change at 5 yr 
   Mean difference 
   p-value 
 
0.201+0.044 
0.005+0.050 
-0.011 
0.16 
 
0.189+0.041 
0.026+0.054 
0.010 
0.17 
 
0.187+0.045 
0.016+0.048 
0 (reference) 
Albumin excretion rate 
(mcg/min) 
   Mean at baseline 
   Mean at 5 yr 
   Mean difference 
   p-value 
 
 
6.3+4.6 
6.9+7.8 
1 
0.74 
 
 
6.5+6.7 
14+36.1 
8 
0.007 
 
 
6.4+6.2 
5.3+3.9 
0 (reference) 
GFR (mL/min) 
   Mean at baseline 
   Mean at 5 yr 
   Mean difference 
   p-value 
 
129+20 
123+20 
0.4 
0.88 
 
131+18 
121+21 
-1.5 
0.54 
 
126+22 
120+22 
0 (reference) 
 
  Microalbuminuria 5-year cumulative incidence was higher with losartan than with placebo (17% vs 6%, 
p=0.01) but was not significantly higher with enalapril (4% vs 6%, p=0.96)  
Authors’ 
Conclusion 
  Did not detect structural or functional benefits on nephropathy from the blockade of the RAAS with an ACE-I 
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Comments    Examined AER, GFR, and renal morphological features 
  Interesting that more patients in the losartan group progressed to microalbuminuria 
  Results similar to the Collaborative Study Group’s captopril trial  benefit with captopril seen in patients with 
advanced nephropathy, but not seen in patients with SCr < 1.5 mg/dL 
 
 
V.  Summary 
a.  Glycemic control has been proven to be effective in preventing microvascular complications, including 
diabetic nephropathy 
b.  RAAS blockade has been shown to be effective in preventing or slowing progression of micro- or 
macroalbuminuria in T1DM and T2DM patients with hypertension and/or some evidence of micro- or 
macroabluminuria 
c.  RAAS blockade was shown to be effective in preventing nephropathy in T1DM patients with pre-
existing microalbuminuria and T2DM patients with hypertension without nephropathy  
d.  RAAS blockade was not shown to be beneficial in preventing diabetic nephropathy in normotensive and 
normoalbuminuric T1DM or T2DM patients 
 
Table 5.  Summary of recommendations from trials: ACE-I or ARB for diabetic nephropathy? 
T1DM or T2DM  HTN  Retinopathy  Diabetic 
nephropathy 
CVD or CVD 
risk factors  ACE-I or ARB? 
T1DM  +  +  +  -  YES 
T2DM  -  -  +/-  +  YES* 
T2DM  +  -  +  -  YES 
T2DM  +  -  +**  -  YES 
T2DM  +  -  +^  -  YES 
T2DM  +  -  -  -  YES 
T2DM  -  -  -/+  +  NO/YES 
T1DM  -  -  -/+**  -  NO/YES 
T1DM   -  -  -  -  NO 
T1DM  -  +/-  -  -  NO 
T2DM  -#  +  -  -  NO 
* Combination therapy effective in reducing proteinuria, but overall worsens major renal outcomes 
** Microalbuminuria  ^ Macroalbuminuria  # Normotensive or treated with a non-RAAS antihypertensive 
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VI.  Clinical controversy 4 
a.  Proteinuria as a surrogate outcome for CKD? 
b.  National Kidney Foundation (NFK)-KDOQI work group concluded 
i.  There is insufficient evidence for acceptance of changes in proteinuria as a surrogate outcome for 
progression of early diabetic kidney disease 
ii.  However, failure to reduce albuminuria does not eliminate a beneficial clinical effect of diabetic 
kidney disease from a potential intervention 
iii.  To be considered efficacious, potential treatments for diabetic nephropathy must show benefits on 
albuminuria reduction, and also on clinical endpoints (eg. Stage 5 CKD, cardiovascular disease, 
death) 
c.  What about all the previous trials with endpoints for proteinuria? 
 
VII. Recommendations 
a.  Achieve glycemic control (goal HgbA1c < 7%) 
b.  Would initiate RAAS blockade (ACE-I or ARB) in 
i.  T1DM or T2DM patients with evidence of albuminuria with or without hypertension 
ii.  T2DM patients without albuminuria with hypertension 
c.  Would not initiate RAAS blockade (ACE-I or ARB) in 
i.  T1DM or T2DM normotensive patients without albuminuria 
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